Ana Lucia Yañez Felix

Dr. Ana Lucia Yañez Felix

LIEM, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Clinical Genetics
Verified
Journal Article
Open access
APAlistair T. Pagnamenta
Alistair T. Pagnamenta
RBRebecca S. Belles
Rebecca S. Belles
BSBonnie Anne Salbert
Bonnie Anne Salbert
IWIngrid M. Wentzensen
Ingrid M. Wentzensen
MSMaria J. Guillen Sacoto
Maria J. Guillen Sacoto
GCGenomics England Research Consortium
Genomics England Research Consortium
PKDCC encodes a component of Hedgehog signalling required for normal chondrogenesis and skeletal development. Although biallelic PKDCC variants have been implicated in rhizomelic shortening of limbs with variable dysmorphic features, this association was based on just two patients. In this study, data from the 100 000 Genomes Project was used in conjunction with exome sequencing and panel-testing results accessed via international collaboration to assemble a cohort of eight individuals from seven independent families with biallelic PKDCC variants. The allelic series included six frameshifts, a previously described splice-donor site variant and a likely pathogenic missense variant observed in two families that was supported by in silico structural modelling. Database queries suggested that the prevalence of this condition is between 1 of 127 and 1 of 721 in clinical cohorts with skeletal dysplasia of unknown aetiology. Clinical assessments, combined with data from previously published cases, indicate a predominantly upper limb involvement. Micrognathia, hypertelorism and hearing loss appear to be commonly co-occurring features. In conclusion, this study strengthens the link between biallelic inactivation of PKDCC and rhizomelic limb-shortening and will enable clinical testing laboratories to better interpret variants in this gene.

7 November 2024 in Life
Verified
Journal Article
Open access
PDF file
NMNamibia Mendiola
Namibia Mendiola
CCCecilia Contreras-Cubas
Cecilia Contreras-Cubas
FBFrancisco Barajas-Olmos
Francisco Barajas-Olmos
JBJose Rafael Villafan Bernal
Jose Rafael Villafan Bernal
AFAna Lucia Yañez Felix
Ana Lucia Yañez Felix
LOLorena Orozco
Lorena Orozco
Cystic fibrosis (CF) is a rare autosomal recessive disease most commonly affecting the Caucasian population. CF diagnosis can be a challenge due to the large spectrum of pathogenic variants in the CFTR gene and the effects of complex alleles. Next-generation sequencing has improved our understanding of the contribution of these complex alleles to the wide spectrum of CF clinical symptoms and to the response to medications. Herein, we studied nine CF patients from six unrelated families carrying the complex allele p.[Ile148Thr;Ile1023_Val1024del] with a frequency of 0.18%. All patients were from Central Mexico. This complex allele was found in trans with Class I and II pathogenic variants such as p.(Phe508del), and p.(Phe1078Profs*77)]. A targeted search of a dataset of 2217 exomes from healthy individuals revealed that eight individuals (0.18%) carried the p.(Ile148Thr) variant, but only one (0.022%), who was also born in Central Mexico, was a carrier of the complex allele. These findings show an enrichment of this p.[Ile148Thr;Ile1023_Val1024del] complex allele in Mexican CF patients in this region of Mexico. Finally, protein modeling revealed that this complex allele disrupts the secondary structure of the CFTR protein and might alter the ion flow.

3 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NMNamibia Mendiola
Namibia Mendiola
CCCecilia Contreras-Cubas
Cecilia Contreras-Cubas
FBFrancisco Barajas-Olmos
Francisco Barajas-Olmos
JBJose Rafael Villafan Bernal
Jose Rafael Villafan Bernal
AFAna Lucia Yañez Felix
Ana Lucia Yañez Felix
LOLorena Orozco
Lorena Orozco
Cystic fibrosis (CF) diagnosis can be a challenge due to the large spectrum of pathogenic variants in the CFTR gene and the effects of complex alleles. Next-generation sequencing has improved our understanding of the contribution of these complex alleles to the wide spectrum of CF clinical symptoms and to the response to medications. Herein, we studied nine CF patients from six unrelated families carrying the complex allele p.[Ile148Thr;Ile1023_Val1024del] with a frequency of 0.18%. All the patients were from Central Mexico. This complex allele was found in trans with Class I and II pathogenic variants (PVs) such as [c.1521_1523del, p.(Phe508del), and c.3231_3232del, p.(Phe1078Profs*77)]. A targeted search of a dataset of 2,217 exomes from healthy individuals revealed that eight individuals (0.18%) carried the p.(Ile148Thr) variant, but only one (0.022%), who was also born in Central Mexico, was a carrier of the complex allele. These findings led us to hypothesize a founder effect for the p.[Ile148Thr;Ile1023_Val1024del] complex allele in Mexican patients with CF, probably through migration from the French-Canadian population in Mexico. Finally, protein modeling revealed that this complex allele disrupts the secondary structure of the CFTR protein and might alter the ion flow.

26 June 2026 in Prenatal Diagnosis
Verified
Journal Article
Open access
LLLópez‐Rodríguez Larissa
López‐Rodríguez Larissa
LMLuis Felipe León Madero
Luis Felipe León Madero
JSJiménez‐Chaidez Salvador
Jiménez‐Chaidez Salvador
GMGallardo‐Gaona Juan Manuel
Gallardo‐Gaona Juan Manuel
RJRodríguez‐Sibaja María Jose
Rodríguez‐Sibaja María Jose
RMRosalba Sevilla Montoya
Rosalba Sevilla Montoya
Objective: To review the published literature on prenatal findings of COL2A1 ‐related SEDC, summarizing reported imaging and molecular variants, and to describe two additional prenatal cases evaluated at a tertiary referral center. Method: A narrative review with a systematic search strategy was conducted to analyze prenatal imaging findings, gestational age at detection, and molecular diagnoses in cases of COL2A1 ‐related SEDC. Clinical and molecular description of two additional fetal cases with postnatal molecular confirmation were also included. Results: Gestational age at initial detection ranged from 11 to 28 weeks. Five reported cases occurred in a familial setting, while two were initially considered sporadic. In several cases, complementary imaging modalities were required to better characterize vertebral and ossification defects. A clear genotype–phenotype correlation could not be reliably established; no specific molecular pattern reliably predicted the severity of prenatal imaging findings or perinatal outcomes. Conclusion: Our findings highlight the nonspecific nature of prenatal manifestations in COL2A1‐related SEDC, which despite being largely consistent across cases do not allow for a specific diagnosis without molecular confirmation or a known family history. These challenges underscore the need for a comprehensive diagnostic strategy that integrates detailed imaging, molecular genetic testing, and close collaboration within a multidisciplinary team.